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Background: Placebo effects are mediated by expectancy, which is highly influenced by psychosocial factors of a
treatment context. These factors are difficult to standardize. Furthermore, dedicated placebo research often
necessitates single-blind deceptive designs where biases are easily introduced. We propose a study protocol
employing a virtual experimenter – a computer program designed to deliver treatment and instructions – for the
purpose of standardization and reduction of biases when investigating placebo effects.
Methods: To evaluate the virtual experimenter’s efficacy in inducing placebo effects via expectancy manipulation,
we suggest a partially blinded, deceptive design with a baseline/retest pain protocol (hand immersions in hot
water bath). Between immersions, participants will receive an (actually inert) medication. Instructions pertaining to
the medication will be delivered by one of three metaphors: The virtual experimenter, a human experimenter, and
an audio/text presentation (predictor “Metaphor”). The second predictor includes falsely informing participants that
the medication is an effective pain killer, or correctly informing them that it is, in fact, inert (predictor “Instruction”).
Analysis will be performed with hierarchical linear modelling, with a sample size of N = 50. Results from two pilot
studies are presented that indicate the viability of the pain protocol (N = 33), and of the virtual experimenter
software and placebo manipulation (N = 48).
Discussion: It will be challenging to establish full comparability between all metaphors used for instruction
delivery, and to account for participant differences in acceptance of their virtual interaction partner. Once
established, the presence of placebo effects would suggest that the virtual experimenter exhibits sufficient cues to
be perceived as a social agent. He could consequently provide a convenient platform to investigate effects of
experimenter behavior, or other experimenter characteristics, e.g., sex, age, race/ethnicity or professional status.
More general applications are possible, for example in psychological research such as bias research, or virtual reality
research. Potential applications also exist for standardizing clinical research by documenting and communicating
instructions used in clinical trials.
Keywords: Virtual reality, Placebo mechanisms, Placebo analgesia, Bias, Blinding, StandardizationBackground
To a large extent, placebo effects arise from the psycho-
social setting in which a treatment is delivered, most not-
ably the physician/patient or experimenter/participant
interaction [1]. These effects can be substantial [2, 3].
However, it is difficult to systematically tease apart the
contributions made by separate aspects of an interaction.* Correspondence: bhoring@clemson.edu
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as a platform to address these issues with minimized risk
of bias.
We define the placebo effect (PE) as that part of an ac-
tually experienced symptom improvement mediated by
psychological expectancy concerning a treatment, regard-
less of the treatment’s actual efficacy [4]. This expectancy
arises from multiple sources in the treatment’s psycho-
social context, such as verbal instruction [5], conditioning
[6] or social learning [7].le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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Fig. 1 “Dr. Halsey”, the virtual experimenter
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clinical trials, where the placebo group receives an inert
treatment to serve as control for the actual treatment
[8]. However, the change happening in the placebo
group is always a composite measure, including the ac-
tual placebo effect and numerous other factors [9, 10].
Some of these are a feature of the nosological subject
matter, such as the natural course of disease and the fact
that people tend to seek out treatment at peaks of symp-
tom severity. These factors can lead to regression to the
mean, which describes the fact that extreme values will
tend to converge toward less extreme values at retest.
Other factors include distinct psychological phenomena,
like response biases, which cause study participants to
modify their answering behavior after receiving a pla-
cebo treatment, without actually affecting their symptom
experience [9, 10].
To investigate PEs per se, dedicated research involving
additional control groups has been performed. Different
from classical clinical trials where the placebo group is the
control group, dedicated placebo research inquires into
the conditions in which PEs occur, and the mechanisms
involved [11]. A number of paradigms exist which employ
active treatments [11, 12]. For example, in the “balanced
placebo design” [13], the actual treatment (active vs. inert)
is paired with the information with which it is adminis-
tered (“active” vs. “inert”). Like double-blind clinical trials,
this permits blinding. However, use of active treatment is
often precluded due to ethical and regulatory obstacles.
Especially when investigating healthy participants to iden-
tify basal mechanisms of the placebo response, this fre-
quently leads to the employment of more basic designs.
One of these designs is a single-blind deceptive placebo
design. For example, in one of our own studies [14], two
groups receiving the same inert treatment were compared,
with one of them being (deceptively) told that the treat-
ment is actually effective, and one being (truthfully) told
that it is not. Under these circumstances, the above men-
tioned psychological confounds can be exacerbated. Not
only are the investigated variables highly affected by psy-
chological influences to begin with, but additionally, blind-
ing of the experimenter is frequently impossible or
impractical [10]. Consequently, while great progress has
been made in identifying the neuropharmacological [15],
neuronal [16] and even genetic [17] underpinnings of pla-
cebo responsiveness, some of this research stands on
shaky foundations [10]. If the experimental interaction is
not tightly controlled, it is difficult if not impossible to es-
tablish causation in placebo trials: The reported symptom
change of a participant cannot merely be attributed to the
(intentional) treatment difference, but possibly to subtle
but systematic (unintentional) differences in the broader
experimental context. These differences contribute to a
mean difference of experimental group versus controlgroup. Some of these context factors have been explored,
such as experimenter variables like a reassuring, positive
attitude [18], empathy [1], affect-oriented communication
[19], professional status [20] or sex [21]. However, these
studies have been rarely replicated.
We propose that some of the limitations of research
addressing psychological entities like symptom experi-
ences could be overcome by the use of a virtual experi-
menter (VEx; Fig. 1). The VEx is a computer program
designed to perform the function of randomized treat-
ment allocation and treatment delivery. While preserv-
ing or even exceeding psychosocial characteristics of a
conversation [22] (which are required for PEs to arise in
the first place), it would perform social tasks with
complete standardization – this is in contrast to pre-
recorded messages, which do not induce the same extent
of social presence as an embodied conversational agent.
From this framework, it is easy to manipulate aspects
of the instruction or the appearance of the VEx without
changing any of the other parameters, as would almost
necessarily be the case if the task were performed by a
human experimenter (HEx). While virtual reality has
been used in some related applications before (e.g., as
“virtual reality-based analgesic” distraction techniques
[23] or interview partners [24] in the scope of psycho-
logical research), its use for the proposed purpose has
not been investigated.
In the following, we present a comprehensive study
protocol to test the VEx’ efficacy in eliciting PEs, to es-
tablish its viability as a substitute for treatment alloca-
tion and delivery by a HEx (section “Methods”). Due to
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cebo analgesia), a pain modality will be employed as the
method for symptom induction. The protocol combines
several features (virtual reality software and pain proto-
col). These components have been separately investi-
gated in pilot studies presented following the proposed
protocol (section “Current status”). We outline the cre-
ation of the VEx under “Development of the stimulus
material”, and its evaluation under “Pilot study 1”. To
assess reproducibility and possible carry-over effects, we
conducted a pilot study of the pain protocol, as well.
Core findings are presented under “Pilot study 2”.
Methods
We propose the following methods to determine the
VEx’ efficacy in inducing PEs. The interaction with the
VEx will be compared to an HEx interaction, and an
audio/text based interaction. All non-interventional in-
teractions such as the pain testing will be performed by
a blinded laboratory assistant.
Design
The study will follow a partially blinded, deceptive, re-
peated measures design. Participants will undergo a base-
line pain measurement (five 60 s immersions of the hand
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Fig. 2 Experimental design (A) and participant verbal input during the inte
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interaction sections, the arrows indicate the time points of verbal input reqwith a supposed pain killer, and a retest pain measure-
ment. In this design, every participant will only receive an
oral placebo (no active medication), but groups will differ
as to the instruction about the (actually inert) “medica-
tion’s” efficacy.
Within-persons and between-persons predictors include
■ the mode of treatment/instruction presentation
(between-persons predictor METAPHOR, 3 levels:
HEx, VEx, text/audio)
■ the instruction itself (between-persons predictor
INSTRUCTION, 2 levels: “medication” (deceptive) vs.
“inert” (truthful)); this manipulation is double-blind
to both participant and laboratory assistant
■ the pain measurement repetition, which constitutes
nested within-persons predictors (immersion TIME
nested in immersion TRIALS nested in immersion
SEQUENCES). In the scope of this study outline, we
will only address TRIALS and SEQUENCES pertaining
to the expected results.
See Fig. 2a for a design and protocol outline. Within-
persons and between-persons predictors correspond to
level 1 and level 2 variables used in hierarchical linear
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Participants will be recruited from Clemson University's
student population, staff and faculty. Exclusion criteria will
be applied (Table 1). We will balance the sample for sex/
gender and will attempt mean matching for age, to yield
roughly equal distributions in all combinations of the two
between-persons predictors. Both sex/gender and age are
possible confounds, as they may influence pain sensitivity
[25, 26], placebo responsiveness [27] or the reception of
the technology involved in the intervention [28].
Due to the deceptive nature of the protocol, full informed
consent cannot be procured prior to participation; instead,
a cover story will be presented to the participants. After the
experiment, participants will receive full disclosure of the
manipulation. Express permission will be asked of them to
consider their data in the analysis. They will be given the
choice to withdraw their data from analysis at any point
prior to publication, without the need for justification.Procedure
Participants will continually rate their pain during SEQUENCE
1 under supervision of a laboratory assistant. They will then
be randomly assigned to one of the 3(METAPHOR)x2(IN-
STRUCTION) experimental groups. In a separate room, they
will interact with the METAPHORS delivering the INSTRUC-
TIONS. For the VEx and audio/text condition, interactional
components are displayed in Fig. 2b. Crucially, neither as-
signment will be revealed to the laboratory assistant.
During the placebo manipulation, the inert medication
will be automatically dispensed using a self-constructed
pill dispenser controlled by an Arduino platform
(https://www.arduino.cc/). For VEx and audio/text con-
dition, pill dispension will be performed by the presenta-
tion software; in the HEx condition by pressing a button.
An overall inter-SEQUENCE interval of 35 min will be
observed for cutaneous sensitivity to recover, and to
provide a plausible cover story for the medication to
take effect (in the “medication” instruction).
The pain change at retest, compared between experi-
mental groups, will be the main outcome.Table 1 Inclusion criteria for the proposed study
18 < Age < 64
No past or present brain or nerve conditions (e.g. fainting, stroke, neuropathy)
No past or present pain disorder (e.g. diagnosed migraine, chronic back pain)
No open wounds or skin conditions on the dominant hand (e.g.
hangnail, graze)
Abstained from recreational drugs (alcohol, cannabis) for at least 24 h
before the lab visit
Abstained from pain medication (and other medication feasibly
affecting experimental parameters) for at least 24 h before the lab visitPain protocol
For symptom induction, we will employ a hot water bath
(RTE-111, Neslab Instruments, Inc., Newington, NH), which
is an established method for painful stimulation [29, 30].
Tonic heat pain has been successfully employed in the con-
text of placebo studies with comparable stimulus strengths
[31, 32]. Participants will be asked to immerse their domin-
ant hand in the water kept at a constant temperature of 47 °
C, which is painful for most people [33]. They will be in-
formed that they can discontinue the experiment at any
time. Two familiarization trials will be given where partici-
pants briefly put their hand in and out of the water. They
will then be asked to immerse their hand for 1 min, take it
out for 30 s, put it back in for 1 min etc., for a maximal
number of 5 immersions (total immersion time 5 min).
Immersion and removal will be prompted by automated
verbal displays on screen, and accompanying audio signals.
Throughout the sequence, participants will continually
rate their pain experience with a 0 to 100 digital visual
analogue scale (VAS) displayed on a touch screen. They
will be asked to leave their finger on the screen and
move it once their pain perception changes.
After an interval of 35 min, another sequence of 5
immersions will be performed. After each sequence, they
will also give a single retrospective rating of pain inten-
sity and unpleasantness (VAS from 0 to 100) to establish
comparability to conventional non-continuous measures.
Predictor METAPHOR: virtual experimenter, human
experimenter and audio/text condition
Identical instructions will be delivered by the three META-
PHORS. They will consist of a brief introduction of the
agent delivering the instructions (VEx, HEx or disembod-
ied voice), a cover story explaining the (actually fictional)
background of the experiment, and the treatment alloca-
tion constituting the placebo manipulation. Participants
will also interact with the VEx and audio/text condition in
the scope of a frequently-asked questions (FAQ) module;
the HEx will also provide the list of FAQs and will attempt
to restrict the interaction to these. The questions revolve
mostly around aspects of the experimental protocol, like
they would in a naturalistic conversation with an HEx.
The VEx behavior includes looped idle animations,
conversation-triggered gestures, and facial expressions. Ex-
perimental instructions were prerecorded by a voice actor
and lip-synchronized with the virtual agent. The audio/text
METAPHOR includes the same voice recording as the VEx
METAPHOR (Fig. 3a), but displays text instructions alongside
the recording, instead of the virtual agent (Fig. 3b). This
condition is included to gauge the relevance of visual social
cues beyond the verbal content of the instruction.
Additional details pertaining to the software employed in
the experiment is provided below (see section “Current
status”).
Fig. 3 Visual display of two of the three METAPHORS; the audio output is identical between both. a1/a2 The VEx “Dr. Halsey” while gesturing.
b1/b2 Audio/text condition during the segments corresponding to a1/a2
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The placebo manipulation is contained in the INSTRUC-
TION received by the participant around the dispension
of “medication”. It consists of the exchanging of a single
sentence, stating either
“you have been assigned to the open-label treatment
condition. This means that the pills you will receive
are definitely the study medication” (in the
“medication” INSTRUCTION)
or
“you have been assigned to the open-label control con-
dition. This means that the pills you will take are pla-
cebo pills, that is, contain only an inactive substance”
(in the “inert” INSTRUCTION).To reinforce group allocation, two side effect question-
naires will be answered by the “medication” group only
– one directly after placebo manipulation, the other at
the end of the intermission. Furthermore, only “medica-
tion” group participants will be asked about their prior
experience with the study drug, how effective it was in
their experience, and how effective they assume it will
be in reducing the pain at retest.
Secondary measures
A number of putative predictors of pain sensitivity and
placebo responsiveness [34] will be assessed before and
during the experiment. These variables will be used as
adjunct within- and between-persons predictors (covari-
ates) of changes in pain sensitivity.
Psychological measures include pain questionnaires
as well as several other psychological trait and state
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asked about their desire for pain relief, and the expect-
ation of pain relief after receiving the “medication” [5].
Physiological measures include heart rate as a proxy of
general autonomic arousal [35] and high-frequency heart
rate variability as a dedicated measure of parasympa-
thetic withdrawal (cf. [36]). Furthermore, blood pressure
[37] and skin temperature of the immersed hand [38]
will be included as putative predictors of heat pain sensi-
tivity. Heart rate and heart rate variability will be
assessed with a Biolog device with Fetrodes technology
(UFI, Morrow Bay, CA) during a 5 min physiological
baseline, and during the measurements themselves (each
sequence lasting 7.5 min). Blood pressure will be
assessed with a calibrated GE Dinamap Pro100 (Medical
Solutions, Minneapolis, MN) device. The last four of five
measurements, spaced 1 min apart [39], will be averaged
to derive systolic and diastolic blood pressure. Blood
pressure will only be assessed during the physiological
baseline, as cuff inflations could distract from the pain
stimulation. Skin temperature will be assessed with an
infrared thermometer before and after each SEQUENCE,
as well as at multiple time points during the
intermission.
Bias reduction and manipulation check
A manipulation check will be performed assessing any
doubts or suspicions concerning the treatment allocation
or the cover story. Preliminary data indicates that the cover
story, including the group allocation, are consideredTable 2 Putative predictors of pain sensitivity and placebo responsi
Questionnaire/scale Construct
Trait questionnaires, answered in online survey before coming to the lab
Pain Related Self Statements
inventory (PRSS)
Coping with pain, catastrophizing ab
Pain Vigilance and Awareness
Questionnaire (PVAQ)
Attentional focus on pain
Pain Sensitivity Questionnaire (PSQ) Sensitivity to various painful stimuli
Beliefs about Medicines
Questionnaire (BMQ)
Attitudes towards medical profession
Beliefs in Expectation Biases Beliefs to what extent perception is i
expectations
International Personality Item Pool
Big Five scales (IPIP B5)
Extraversion, agreeableness, conscien
emotional stability, intelligence/imag
Internality, Powerful Others, and
Chance scales (IPC)
Attribution of events to personal con
individuals, chance
Revised Life Orientation Test
(LOT-R)
Positive/negative expectation of outc
dispositional optimism/pessimism
State questionnaires, answered during the lab visit




tirednessconvincing by the participants: 18 of 19 people answered
“no” to a post-experimental question asking “Did you at
any point find the experimental instructions
unconvincing?”.
Allocation to the experimental groups will happen in a
room adjacent to the room where the pain measurement
takes place, and without insight of the laboratory assist-
ant into the allocation. He or she will therefore be fully
blinded to the treatment allocation when performing the
retest. Measures will be taken to ensure that allocation is
not revealed by the participant: The participant will be
asked by the VEx, HEx or audio/text display not to no-
tify the laboratory assistant of their treatment allocation,
and the laboratory assistant will document any devia-
tions. Audiovisual recording of the participant/labora-
tory assistant-interaction will be considered if necessary.
All measurements (except blood pressure and skin
temperature) and pain reports will be performed on a
computer without communication with the laboratory
assistant. Furthermore, the instructions for the continu-
ous pain ratings contain a line to emphasize participant
anonymity and non-involvement of the laboratory assist-
ant in data analysis, “This next part is very important:
Your ratings will be analyzed by a blinded experimenter
only after the session is over. Focus as much as possible
on the sensation in your immersed hand, and feel totally
free to rate your pain precisely and truthfully. Try not to
let my presence or any other thought affect the way you
report the sensation, or affect the number of trials you
complete.” Also, during the pain measurement, theveness
Example item
out pain “If I stay calm and relax, things will be better.”
“I am quick to notice changes in location or extent
of pain.”
“Imagine you trap your finger in a drawer.”
and pharmaceutics “Medicines do more harm than good.”
nfluenced by “In general, people are likely to experience the
mood (good or bad) they expect to experience.”
tiousness,
ination
“I feel comfortable around people.”
trol, other “Whether people act according to my wishes
depends mainly on myself.”
omes = “I’m always optimistic about my future.”
“I get in a state of tension or turmoil as I think over
my recent concerns and interests.”
ess, wakefulness/ “Right now I feel […] content.”
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the immediate vicinity of the participant to sit down at a
table in the participant's field of view, but facing in the
same direction as the participant as to not give the par-
ticipant the feeling of being observed (beyond an initial
making sure that all instructions are complied with).
Some extent of selection bias is expected, as an aver-
sive stimulation is employed. While a monetary compen-
sation of $20 is offered for the ca. 2 h experiment, pain
sensitive people will be potentially underrepresented in
the sample. Systematic deviations from the norm will be
assessed by analyzing questionnaire data (specifically, re-
ported pain sensitivity via the PSQ) and actual respond-
ing to the stimulus. Preliminary data does not suggest
that this is a serious issue, with roughly normally distrib-
uted pain sensitivity (data not shown).
Analysis and sample size estimation
Data entry is almost fully automated via the touch-screen
interface (for continuous pain ratings), a digital survey tool
(for other pain ratings and psychological measurements),
and on-line registration of physiological parameters. The
exception are blood pressure and temperature data which
are documented on a score sheet. Continuous pain ratings
will be recorded at a sampling rate of ca. 40 Hz, but down-
sampled to 1 s means for analysis.
Data will be analyzed with hierarchical linear model-
ling (HLM). Among other strengths, this approach en-
ables us to consider both categorical and continuous
predictor variables (e.g., covariates), and the inclusion of
cases with missing values, allowing for the number of re-
peated measures to differ across persons [40]. HLM puts
no constraints on the number of repeated measure-
ments, which permits an analysis of differences in the
time course of pain. HLM also allows for considering
random effects (intercepts and slopes), suitable to the
high interindividual variability of pain sensitivity [41].
The robustness of results will be assessed by outlier ana-
lyses of the regressional models provided by HLM, includ-
ing contrasting of predicted versus actual values,
studentized residuals and Mahalanobis’ distance. Outliers
will be excluded both at the within-person level (individ-
ual measurement occasions) and the between-person level
(exclusion of individuals with outliers). Robustness will be
gauged by changes in the significance of the results.
HLM sample size estimation considers the sample size at
level 1 (n; in our case, the repeated measurements within-
persons) and the sample size at level 2 (N; in our case, the
individual participants). Recommendations vary (e.g.
[42, 43]); Hox [43] suggests larger sample sizes of n= 20 and
N= 50 when investigating cross-level interactions. The
wealth of data points provided by the second-by-second
continuous pain ratings easily allow for meeting the n= 20
suggestion. However, while a total of 600 s of immersionswill be available, the effective sample size will be lower due
to large intraclass correlations, or strong autocorrelation.
Due to the high interindividual variation of pain sensitivity,
we would nevertheless aim for including N= 50 individual
participants to determine difference between the six groups.
Estimating 15 % attrition, the projected sample size there-
fore amounts to N= 58 individuals.Hypotheses and expected results
The PE would be constituted by a larger symptom im-
provement from SEQUENCE 1 to SEQUENCE 2 in the
“medication” INSTRUCTION, than in the “control/placebo”
INSTRUCTION (“medication”(S2-S1)>“control”(S2-S1). This
is a general test of the efficacy of the placebo paradigm,
which is a crucial building block for assessing the effect
of the different METAPHORS.
The design does not strictly permit the establishment of
equivalence between METAPHORS in the sense of a non-
inferiority trial, which is deemed too ambitious at this stage.
For the proposed protocol, a non-significant difference be-
tween VEx and HEx would be considered as a first step to
establish the viability of the VEx (HEx =VEx). On a descrip-
tive level, we are expecting a slightly lower effect induced by
the VEx, but lower variance than under the HEx, amounting
to comparable effect sizes. Beyond that, it is hypothesized
that the audio/text METAPHOR induces a smaller symptom
improvement than the other conditions (HEx =VEx >
audio/text) due to absence of visual social cues.
Using a more fine grained analysis at the TRIAL level
could yield additional information, such that groups dif-
fer in early or late TRIALS only, or that the slope (pain
changes in consecutive TRIALS) is different between
groups. For example, a significant difference between
“medication” vs. “control” could come about by a shal-
lower pain increase in consecutive TRIALS in SEQUENCE 2,
despite identical initial sensitivity (see Fig. 4).
If we indeed do not find significant differences of PEs
induced by the VEx versus an HEx, we will proceed to
more complex protocols (see “Potential and outlook”). If
we do find differences such that an HEx proves superior
to the VEx, we will return to the design phase and ad-
dress weaknesses in the VEx software in an iterative
design-test protocol until we can reliably elicit PEs using
the VEx that are of comparable size with those elicited
by an HEx.Current status
In the following, the development of the virtual experi-
menter is described in more detail. Furthermore, prelim-
inary results from a pilot study pertaining to the VEx
software are summarized (Pilot study 1). Finally, results
from a pilot study pertaining to the pain protocol are














Fig. 4 Possible results on the TRIAL level during SEQUENCE 2
(post-intervention): Lower pain increase within the “medication”
group (dashed line) vs. the “control” group (solid line)
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The design of the VEx “Dr. Halsey” (cf. Fig. 1) was in-
formed by a preliminary survey including eight different
photographs of supposed study physicians. Photographs
were rated by a non-random sample (N = 10) on various
dimensions (e.g., appearing competent and empathetic
[44], trustworthy, believable, and enthusiastic [1, 18])
(data not shown).
The VEx prototype was modeled using MakeHuman
version 1.0.1 and Blender version 2.69 (Blender Founda-
tion, Amsterdam, Netherlands). It is rendered in a Unity
5.1.1 framework (Unity Technologies, San Francisco,
CA, USA) on a 60“ screen display with 3D-capabilities.
Lip-synchronization was performed using faceshift (face-
shift, San Francisco, CA, USA). The software also in-
cludes an interaction module, which enables participants















Fig. 5 Rating (in percent) of the virtual experimenter simulation along 11 s
(white =Message, light grey = Likeability, dark grey = Compelling) composed17” touch-screen display. Voice recognition is performed
via the Microsoft Kinect (Microsoft, Redmond, WA) and
processed using the Kinect Software Development Kit
1.8 (Microsoft, Redmond, WA) within the Unity frame-
work rendering the VEx.
Pilot study 1: evaluation of the virtual experimenter
This study was aimed at informing the direction of fur-
ther development of the VEx, by investigating how the
VEx prototype is perceived by random participants. The
study protocol outlined above will employ a version of
the piloted prototype once all changes according to the
findings of this study have been integrated.
In this pilot study, 48 participants (23 female, 25 male;
age mean ± SD 20.2 ± 2.3) watched the VEx instruction
without actually undergoing the pain protocol, or receiv-
ing the presumed medication. Participants judged the
VEx on an Expectancy Induction Characteristics ques-
tionnaire assessing dimensions considered conducive to
placebo responses (e.g. [1, 18, 19]). The Expectancy In-
duction Characteristics questionnaire was constructed in
our lab and consists of 11 items (semantic differentials).
The items are subsumed in three scales pertaining to
how convincing a person is perceived (scale Message),
how likeable (scale Likeable), and how compelling (scale
Compelling). The scales exhibit decent reliability with
Cronbach’s alpha of .82, .68 and .82, respectively.
Results are presented in Fig. 5. While the VEx was
judged favorably on the Message and Likeability scales,
it received comparatively bad rating on the Compelling
scale. We believe this to be owed to a rather neutral de-
meanor (both in verbal and nonverbal content) displayed
by the model, which has been intentional to establish a
solid baseline of the VEx’s efficacy. However, we are cur-
rently in the process of improving ratings in this scale by
implementing higher behavioral realism (e.g. breathing,40 60 80 100
emantic differentials. Bars with thick borders display the scale means
of the items directly above
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tion (e.g. more inflections during speech, more pro-
nounced facial expressions).
Pilot study 2: evaluation of the pain protocol
To characterize the pain protocol (see above) and estimate
reproducibility across SEQUENCES (including possible carry-
over effects like habituation and sensitization), we con-
ducted a pilot study with only a waiting period between the
two SEQUENCES. All means are provided with standard devi-
ations; significance testing was performed with hierarchical
linear model analysis, cf. “Analysis and sample size estima-
tion” (a more in-depth discussion is beyond the scope of
this article). In this study, we included 33 healthy partici-
pants (21 female, 12 male; age 20.1 ± 2.4). Continuous pain
ratings almost invariably increased within SEQUENCES/be-
tween TRIALS. On average, participants showed substantial
amounts of pain in both SEQUENCE 1 (VAS 46.4 ± 15.0,
range 23.5 to 83.6) and SEQUENCE 2 (VAS 40.8 ± 15.5, range
18.8 to 78.8), with normal distributions on both occasions.
These means constitute a slight but significant overall de-
crease in pain between the two SEQUENCES. Conversely, sin-
gle retrospective ratings show no difference for intensity
(VAS 53.8 ± 17.7 versus 52.6 ± 21.1) and unpleasantness
(VAS 55.9 ± 17.1 versus 55.6 ± 21.3).
The continuous ratings exhibited good reproducibility
(intraclass correlation coefficient(2,1) ρ = .72) between the
two SEQUENCES, comparable to that of the retrospective
ratings of intensity (ρ = .77) and unpleasantness (ρ = .68).
Discussion
Challenges
The two core challenges are the establishment of PEs in a
tightly controlled protocol with only limited “dosing” of
the placebo manipulation, and achieving a sufficient com-
parability of the VEx with the HEx interaction as to mimic
the psychosocial effects necessary for PEs to arise. The
placebo manipulation only contains a verbal expectancy
manipulation comparable to those used in other placebo
experiments (e.g. [5]). However, we chose to limit em-
phasis and enthusiasm on the side of the experimenter as
much as possible, as to introduce as few as possible con-
founding factors at this point. This may mean that the PE
will not be pronounced.
With the VEx, the greatest challenge is to create a suf-
ficient rapport between him and the participant to be
perceived as a social situation. The Ethopoeia concept
[45] posits a substrate neutrality of human versus virtual
agent behavior: as long as social cues are displayed, they
will lead to “mindless responses” [45], p. 83). However,
these cues go beyond the behavioral realism of the dis-
play (e.g. facial expressions, gestures, blinking, breathing)
– which is necessary but not sufficient [46] – and extent
to interactional components to attribute agency to thevirtual agent, such as turn-taking, visual attention to in-
terlocutors, and behaviors reducing inter-personal dis-
tance. While technology like the “rapport agent” exists
[47, 48], which has been tailored to naturally engage
humans in conversation, our VEx software does not yet
exhibit the same capabilities. At this stage, the VEx in-
cludes an FAQ module, engaging participants to ask
questions with prerecorded answers; furthermore, verbal
input will be required from the participants at certain
points of the protocol to continue (cf. Fig. 3b). However,
in future iterations, actually artificial intelligence-driven
conversation is planned [49], engaging participants in
personal questions e.g. about demographic variables in a
small talk/rapport module.
As to the appearance of the VEx, a balance will be
struck between realism and acceptance – specifically,
the design has to avoid the so-called “uncanny valley”
[50] describing an aversive perception of almost-but-not-
quite realistic artificial agents by human spectators.
Limitations
The rationale of using the VEx in the context of experi-
mental studies makes the assumptions that the treat-
ment delivery and the accompanying instructions are, in
fact, the most important aspects for the generation of
PRs. While instructions alone have been shown to effect
PEs [5, 51, 52], it has been demonstrated that condition-
ing paradigms may have better results [6]. However, a
conditioning approach was considered too logistically
demanding at this stage.
It is possible that the control group itself will not fully
believe in the veracity of them only receiving inert medi-
cation. However, this would lead to a conservative esti-
mate of placebo effectiveness and is therefore no hazard
to the internal validity of the study. We are also consid-
ering the option of using a no-treatment control (i.e., no
placebo delivery at all) instead of a “control/placebo”
instruction.
While evidence exists that female doctors are esti-
mated to have better explanation skills and technical
skills and have a higher acceptance [53], the decision to
only include male models in the creation of the VEx was
made for opportunistic reasons (having a male voice
actor available).
On a more general note, while the main intention be-
hind the creation of the VEx is the assessment and abol-
ishment of biases in psychological and medical research,
there is a possibility that the use of a virtual agent would
induce biases of another sort, such as involving computer
(il)literacy or opinions towards technological progress
[54]. For example, it is feasible that older participants
would have a different response to the VEx’ than younger
participants, who will have been exposed to virtual reality
technology to a higher extent. On the plus side, there is
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formation to a virtual agent than a human experimenter [55,
56], which may be of relevance with increased interactional
capabilities of the VEx. Nevertheless, generalizability will be
attempted by using a sample beyond student participants.
We are further addressing these issues by post-experiment
questionnaires and demographical data about the experience
with, and daily use of computers and 3D technology.
Furthermore, the novelty of the simulation may serve
to accentuate or alleviate effects which would otherwise
be (in)effective. The experience of novelty will be
assessed and investigated as a potential moderator of
treatment efficacy.
Potential and outlook
The broader objective of investigating the VEx is to esti-
mate its comparability to a real human. Using a placebo
paradigm is considered an optimal testbed of this com-
parability due to its dependence on psychosocial vari-
ables. Regardless of outcome pertaining to the efficacy of
the VEx, results from this study will be disseminated to
a wider public, since they will contain valuable informa-
tion on the specific mechanisms involved in the gener-
ation of PEs. Success of the study therefore does not
hinge on the efficacy of the VEx, only on replicating re-
sults from previous placebo manipulations by the HEx.
Should it be established that the VEx can, in fact, serve
as a substitute to an HEx, the possible applications in
medical and general psychological research are many. Fur-
thermore, it should be kept in mind that while a VEx
would prove to be of great value for placebo research, ap-
plicability goes far beyond this narrow topic and extends
into most forms of psychological experiments where
standardization is of relevance. These applications fall into
three interrelated categories – standardization, experi-
mental modification, and communication. To these ends,
we are making efforts to develop the software such that it
can be easily adopted by other researchers, for whom it
would eventually be made available.
Standardization of experimenter characteristics would
facilitate the investigation of psychological entities feas-
ibly affected by psychosocial interactions. As no repeated
acting/performance would be required, a VEx could
serve as a “perfect confederate” [57], p. 6) in social psy-
chological studies, or studies involving social learning. A
VEx would get rid of experimenter-side biases due to
unblinding, especially if being a stakeholder in an exper-
iment’s success or other factors would incentivize an
HEx to guess treatment allocations or behave differently
according to which group one is assigned to, introducing
experimenter demand characteristics [58].
For placebo research, the putative role of experimenter
variables has been elaborated above. Yet, these factors
have been underreported [59], introducing confoundersand thus exacerbating the problems created under non-
blind conditions. One reason for this is the difficulty of
assessing or standardizing these factors. Not only could
a VEx serve as a perfectly standardized platform if these
factors are sought to be held constant: Instead, it would
provide a convenient means to modify single aspects of
the experimenter characteristics while holding all others
equal – such as gender, age or professional role of the
experimenter, or informational content such as the
phrasing of instructions. This would not only inform the
respective research (e.g. about placebo mechanisms), but
also the creation of virtual agents used as interfaces in
customer relations and medical devices.
Furthermore, with a VEx interface, participant behavior
could be monitored much easier, for example by logging
which questions are asked by the participant. While it will
strongly depend on the concrete experimental context if a
VEx can exhaustively serve the informational needs of a
participant, pilot studies could inform the formulation of
frequently asked questions to be covered by the VEx.
Lastly, the standardization aspect not only applies to
single experiments, but to collaborative, multi-center re-
search efforts as well. Since the communication effectively
only entails distribution of software, it could serve as an
easy means to establish instruction equivalence. This is
particularly relevant considering that insufficient reliability
poses serious economic and scientific problems for ran-
domized controlled trials [60, 61], with even double-blind
conditions being no safeguard against yielding biased re-
sults [62]. It is conceivable that outsourcing suitable study
tasks (like consent, instructions, medication, questionnaire
administration) would free up resources which could be
spent on other activities, reducing a trial’s logistical bur-
den. The VEx could be used as best practice example or in
training videos. It could contribute to advances in tele-
medicine or similar situations where a virtual human
interface has been shown to increase usability, e.g., with
elderly people [63]. With the preservation of social cues,
the possibility of instruction delivery via different telecom-
munication devices could prove invaluable for ambulatory
treatment where improvement in compliance and treat-
ment efficacy are sought.
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